Revlimid (lenalidomide) - Important Safety Information from Celgene as approved by the Irish Medicines Board
24 October 2011
Important Safety Information communication from Celgene on the risk of second primary malignancies in patients treated with Revlimid (lenalidomide).
Important Safety Information - Revlimid